Germany – Pharmaceutical products – Pharmaceutical discount agreement pursuant to Section 130c(1) SGB V in conjunction with Section 130a(8) SGB V for the active substance Erenumab
Agreement pursuant to Section 130c(1) SGB V in conjunction with Section 130a(8) SGB V on the granting of discounts for patent-protected medicinal products containing the active substance Erenumab (AIMOVIG®). An exact contract value cannot be determined because it depends on
Opportunity description
Agreement pursuant to Section 130c(1) SGB V in conjunction with Section 130a(8) SGB V on the granting of discounts for patent-protected medicinal products containing the active substance Erenumab (AIMOVIG®). An exact contract value cannot be determined because it depends on various unknown factors. The contract value for the awarded contract can therefore only be stated as a notional value based on the currently applicable thresholds. Agreement pursuant to pursuant to Section 130c(1) SGB V in conjunction with Section 130a(8) SGB V on the granting of discounts for patent-protected medicinal products containing the active substance Erenumab (AIMOVIG®) Procedure: neg-wo-call. Review the original TED notice for the complete requirement, lots, amendments and attachments.
Business details are available after sign in
Codes, capabilities, evidence, buyer details and marketplace actions are withheld from the public HTML and API response.